Omnix Medical has begun enrolling patients in a Phase II trial of OMN6, a new antimicrobial compound designed to physically disrupt pathogenic bacteria. This breakthrough approach underscores the potential for a novel treatment pathway that could reshape the landscape of antibacterial therapies.